Following the publication of the results of the monarchE trial, the data from real-world studies showed that the monarchE clinicopathological high-risk criteria were associated with an increased risk of recurrence and all-cause mortality in patients with HR+/HER2- early-stage breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.